

Andrea V. Malinowski
Corporate Counsel
DuPont Legal D-7078
1007 Market Street
Wilmington, Delaware 19898
Phone: (302) 774-6443
Fax: (302) 774-4812
E-mail: Andrea.V.Malinowski@usa.dupont.com

February 5, 2001

VIA FEDERAL EXPRESS

Document Control Office
Room G99 East Tower
ATTN: Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street, SW
Washington, D.C. 20460-0001

CONTAINS CONFIDENTIAL BUSINESS INFORMATION

Dear Section 8(e) Coordinator:

Re: 8E-HQ-0300-14676
8E-HQ-0500-14676
8E-HQ-1200-14676

This notice is submitted to the TSCA section 8(e) office and pertains to a potential employee exposure that occurred to a substance similar to that described in the above-identified 8e submissions.

The material tested in the above-referenced 8e submissions is similar to a waste material produced during the manufacture of certain fluorochemicals. The waste material has no commercial use and is disposed of via the on site waste water treatment plant. Under normal operating conditions, no human exposure to this waste material occurs.

However, in September, 1999, it was discovered that this material came in contact with the on-site drinking water supply due to a failure of equipment that isolates the drinking

CONTAINS CONFIDENTIAL BUSINESS INFORMATION

8E- HQ-00-14676
February, 2001

Page 2

water system from manufacturing processes. Employees were informed of this event and subsequent follow up actions. The child of an employee in the first trimester of pregnancy when this event was discovered was born with a neural tube defect. The extent (concentration, duration) of employee exposure, if any, to the material is unknown. No other health effects occurring during the time of this event have been reported by employees.

Based upon information available to date, it is not believed that the material is, per EPA TSCA section 8e guidance [43 FR 11110 (March 16, 1978)], strongly implicated as the cause of any adverse human health effects. But, in view of the recent toxicology results already submitted to the section 8(e) office and considering timing of and potential for exposure, it cannot be determined whether or not the material had an impact on human fetal development. As such, out of an abundance of caution, this information is being submitted under TSCA section 8(e).

Substantiation of our confidentiality claim was included previously with the originally filed 8(e) submission identified above and still applies.

If you need further information or clarification, please contact me at the number given above.

Very truly yours,

Andrea V. Malinowski

CONTAINS CONFIDENTIAL BUSINESS INFORMATION